NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ONMD
OneMedNet Corporation
There isn't enough reported data to score ONMD yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ONMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
ONMD's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ONMD PE Valuation
ONMD has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ONMD Forward outlook
There aren't enough analyst estimates for ONMD to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ONMD on earnings quality, reporting a profit while its opponent remains loss making.
ONMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.50 | -$0.20 |
| Q1 2026 | -$0.40 | +$3.10 |
| Q4 2025 | -$0.60 | +$3.20 |
| Q3 2025 | -$0.70 | +$48.80 |
| Q2 2025 | -$1.30 | +$48.70 |
ONMD is still losing money, but far less than before: $1.50 per share over the past year, against $50.00 at its worst in mid-2024.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ONMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ONMD on profitability, with a higher operating margin.
ONMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $292K | +88% |
| Q1 2026 | $96K | -30% |
| Q4 2025 | $891K | +3327% |
| Q3 2025 | $177K | +25% |
| Q2 2025 | $155K | -32% |
| Q1 2025 | $137K | -45% |
| Q4 2024 | $26K | -92% |
ONMD's revenue is growing: $292,000 last quarter, up 88% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -774% | +557 points |
| Q1 2026 | -2658% | -1035 points |
| Q4 2025 | -346% | +9908 points |
| Q3 2025 | -1263% | +418 points |
| Q2 2025 | -1331% | -250 points |
| Q1 2025 | -1623% | -776 points |
| Q4 2024 | -10254% | -8697 points |
| Q3 2024 | -1681% | N/A |
ONMD's operating margin was −774% last quarter, up 557 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ONMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
ONMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.9M | +$403K |
| Q1 2026 | -$1.5M | +$409K |
| Q4 2025 | -$1.7M | +$344K |
| Q3 2025 | -$1.6M | +$354K |
| Q2 2025 | -$2.3M | -$780K |
| Q1 2025 | -$2M | -$400K |
| Q4 2024 | -$2.1M | +$1.9M |
| Q3 2024 | -$1.9M | -$1.8M |
ONMD has burned cash in almost every quarter: −$7M over the past year, against −$8M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ONMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ONMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +270K shares |
| 1 year | +51% | +2M shares |
| 3 years | +288% | +4.3M shares |
ONMD has 6M diluted shares, up 51% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ONMD Net Leverage
ONMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ONMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 29.2 | Neutral |
ONMD's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ONMD PE vs Healthcare Sector
ONMD has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ONMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.01 | 6.8% above |
| 20 week MA | $6.04 | 11% below |
| 50 week MA | $7.98 | 33% below |
| 100 week MA | $8.66 | 38% below |
| 200 week MA | $29.9 | 82% below |
ONMD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 82% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ONMD on returns for 2026, with the stronger performance.
ONMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $99.4 | $101.0 | +1.6% |
| 2022 | $101.0 | $104.4 | +3.4% |
| 2023 | $104.4 | $8.10 | -92% |
| 2024 | $8.10 | $13.3 | +64% |
| 2025 | $13.3 | $12.7 | -4.5% |
| 2026 YTD | $12.7 | $5.35 | -58% |
ONMD is down 58% so far in 2026, after finishing higher in three of the previous five years.